[Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2].
A N BoykoValentina M AlifirovaI G LukashevichZoya A GoncharovaI V GreshnovaL G ZaslavskyS V KotovN A MalkovaG N MishinYe V ParshinaI Ye PoverennovaL N PrakhovaStella SivertsevaI V SmaginaN A TotolyanYu V TrinitatskyT N TrushnikovaF A KhabirovS G ShchurA V ArtemyevaD D BolsunArina V Zinkina-OrikhanYulia N LinkovaPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)
Thus, the assessment of 24 weeks treatment demonstrated that DIV is a highly effective, safe and convenient option for the treatment of RRMS patients, both naive and previously treated with disease modifying therapy. A dose of 500 mg is recommended for further efficacy and safety evaluation during phase 3 CT.
Keyphrases
- placebo controlled
- double blind
- clinical trial
- end stage renal disease
- multiple sclerosis
- chronic kidney disease
- newly diagnosed
- ejection fraction
- phase ii
- open label
- prognostic factors
- computed tomography
- magnetic resonance
- radiation therapy
- study protocol
- combination therapy
- magnetic resonance imaging
- replacement therapy
- image quality
- white matter
- bone marrow
- hiv infected
- preterm birth